A federal judge has certified a class action antitrust suit against pharmaceuticals giant GlaxoSmithKline that accuses the company of using a series of illegal tactics to delay the approval of generic versions of Flonase, a popular allergy drug.
According to the suit, sales of Flonase peaked at $1.3 billion in 2005 — the last year of GSK’s market exclusivity.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
